LH-RH

(redirected from luteinizing hormone-releasing hormone)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to luteinizing hormone-releasing hormone: luteinizing hormone-releasing hormone agonist
References in periodicals archive ?
Kaplan Meier curves of proportion of patients in the short-acting luteinizing hormone-releasing hormone agonist (LHRH-A) treatment arm with testosterone recovery to baseline level in men < 65 years or (n=12) or [greater than or equal to] 65 years of age (n=12).
AEZS-125 is a disorazol Z (AEZS-137) cytotoxic conjugate linked to a Luteinizing Hormone-Releasing Hormone (LHRH)-receptor targeting peptide.
Unlike luteinizing hormone-releasing hormone (LHRH) agonists, such as leuprolide, an established treatment for prostate cancer, FIRMAGON does not induce an initial testosterone surge.
The implant active ingredient, Histrelin, is part of a class of drugs known as luteinizing hormone-releasing hormone (LHRH) agonists.
TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool.
Zoladex is a luteinizing hormone-releasing hormone analogue (LHRH-A), also known as gonadotropin-releasing hormone (GnRH) agonist.
Unlike luteinizing hormone-releasing hormone (LHRH) agonists, such as leuprolide, an established treatment for advanced prostate cancer, FIRMAGON does not induce an initial testosterone surge.
A controlled trial of bicalutamide (Casodex) versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, had been the object of a Phase 3 program in BPH, a non-cancerous enlargement of the prostate which, as announced by the Company last week, did not meet its primary endpoint.
announced today the signing of an agreement with AEterna Zentaris GmbH for the development, registration and marketing of cetrorelix pamoate, a luteinizing hormone-releasing hormone (LHRH) antagonist, for the treatment of benign prostatic hyperplasia (BPH), in the U.

Full browser ?